NOTE 6 –LICENSING AGREEMENTS

The components of licensing agreements, all of which are finite-lived, were as follows:

 SCHEDULE OF LICENSING AGREEMENTS

In February 2025, the Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their Precise PRP (Platelet-Rich Plasma) for both canine and equine products. The exclusive licensing agreement is a five5-year agreement whereby the Company paid an initial licensing fee of $2,000,000, which was paid in a combination of $500,000 cash, $1,000,000 in stock issuances and $500,000 in future contract payments, which is included in accrued expenses as of June 30, 2025, and March 31, 2025. The licensing fee is amortized over sixty (60) months, the term of the agreement. The licensing agreement also has a nominal royalty fee payment between 3% to 4.5%, commencing in the seventh month of the licensing agreement. The royalty fee expense for the three months ended June 30, 2025, and 2024 was $0. We also issued 250,000 warrants, with a strike place of $1.25 per share for a term of three years. The total warrant expense is fair valued at $46,030 to be amortized over thirty-six months. During the three months ended June 30, 2025 and 2024, warrant expense was $3,836 and $0, respectively.

During the three months ended June 30, 2025, and June 30, 2024, amortization expense was $100,000 and $0, respectively.